Pathologic Function – Page 5

Resolution Therapeutics Secures £63.5M in Series B Funding to Advance Macrophage Cell Therapy for Liver Disease

8 months ago talkbio0Tagged Biological Factors, Cell Therapy, Liver diseases, macrophage, physiologic resolution, Regenerative Medicine, Series B

Resolution Therapeutics, Series B funding, macrophage cell therapy, liver disease, regenerative medicine, biopharmaceuticals

Dupixent (Dupilumab) Shows Promising Results in Treating Bullous Pemphigoid, Paving Way for Regulatory Submissions

9 months ago talkbio0Tagged Autoimmune Diseases, biology (field), Bullous pemphigoid, dupilumab, Dupixent, Inflammation

Dupixent, Dupilumab, Bullous Pemphigoid, Autoimmune Disease, Biologic Treatment, Type 2 Inflammation

Roivant Sciences Acquires Experimental Pulmonary Hypertension Drug Mosliciguat from Bayer

9 months ago talkbio0Tagged Bayer, Lung Diseases, Interstitial, Mosliciguat, PH-ILD, Pulmonary Hypertension, Pulmovant, Roivant

Roivant Sciences, Pulmovant, Bayer, Mosliciguat, Pulmonary Hypertension, PH-ILD, Interstitial Lung Disease

GSK’s Depemokimab Shows Promising Results in Phase 3 Trials, Reducing Asthma Attacks by Half

9 months ago talkbio0Tagged Asthma, Depemokimab, IL-5 Inhibitor, Inflammation, Long-Acting Biologic, Phase 3 trials, Severe (severity modifier), SmithKline Beecham

GSK, Depemokimab, Asthma, Phase 3 Trials, Long-Acting Biologic, IL-5 Inhibitor, Severe Asthma, Type 2 Inflammation

Dyne Therapeutics Faces Setbacks Despite Promising DMD Study Results

9 months ago talkbio0Tagged Adverse event, DELIVER (veterinary product), DMD, Duchenne, Dyne veterinary drug, DYNE-251, Executive Departures, Muscular Dystrophy, Muscular Dystrophy, Duchenne

Dyne Therapeutics, Duchenne Muscular Dystrophy (DMD), DELIVER trial, DYNE-251, adverse events, executive departures

FDA Grants Tentative Approval for YUTREPIA, a New Treatment for Pulmonary Arterial Hypertension and Pulmonary Hypertension Associated with Interstitial Lung Disease

10 months ago talkbio0Tagged Associated with, Lung Diseases, Interstitial, PH-ILD, Pulmonary arterial hypertension, Pulmonary Hypertension, regulatory exclusivity, Tentative Approval, Tyvaso, United States Food and Drug Administration, United Therapeutics, YUTREPIA

YUTREPIA, treprostinil, pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), FDA tentative approval, regulatory exclusivity, United Therapeutics, Tyvaso

Merck Acquires Curon’s Bispecific Antibody in $1.3B Deal; Legend Biotech Evaluates Options Amid Probes; Amgen’s FDA Filing Reveals Missing Adverse Events

10 months ago talkbio0Tagged Adverse event, amgen, Antibodies, Bispecific, CAR-T, Carvykti, China, Curon Biopharmaceutical, Evaluation procedure, File (record), Legend Biotech, Merck, United States Food and Drug Administration

Merck, Curon Biopharmaceutical , Bispecific antibody, Legend Biotech, Amgen, FDA filing, Adverse events, China investigations, CAR-T therapy, Carvykti